Advanced tools to spot hereditary cancer risk for patients and families
Official title: Advanced Integration and Validation of Predictive Models for Germline Pathogenic Variant Identification
Funded at Dana-Farber Cancer Inst · NIH-11446768 · Data updated 2026-11-12
A new program will improve how we identify patients with hereditary cancer risk so they can get appropriate genetic testing and potentially targeted treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 10, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $796,311 |
| NIH project number | 1R01CA307720-01A1 |
| Project ID | NIH-11446768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancer who may benefit from germline testing and their families.
✕Less likely to help
Patients without a familial or hereditary cancer risk may not see direct benefits.
What this research studies
This project will combine existing predictive tools and new data to better flag cancer patients who should receive germline genetic testing. By validating and integrating models that consider diverse racial and ethnic backgrounds, it aims to make risk predictions more accurate for all patients. The work will use large datasets from multiple U.S. cancer centers to build a generalizable prediction model for pathogenic germline variants that could guide testing decisions and care.
Why it matters
Potential benefit: If successful, patients at risk for hereditary cancer could be identified earlier, enabling personalized prevention and treatment strategies.
How similar studies have gone: Related models and tools (like PREMMplus and LOHGIC) have shown promise in improving risk prediction but require broader validation across diverse populations.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Uno, Hajime — Dana-Farber Cancer Inst
- Study coordinator: Uno, Hajime
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.